Dual Imaging Heart Catheter Maps Plaque Risk in First Tests

A Dual Imaging Heart Catheter has finished its first tests in people, giving doctors a combined view of artery plaque that current heart scans cannot offer on their own. According to UC Davis, the flexible device travels inside coronary arteries and records both the structure of plaque and its chemical makeup at the same time, a pairing that could flag dangerous deposits before they rupture. The work is still early, and larger trials will decide whether the approach earns a place in everyday cardiac care, but the first human results suggest a scan that reads risk, not just narrowing.

How the Dual Imaging Heart Catheter Works

The device blends two imaging modes in a single slow withdrawal through a vessel. One mode reads the faint natural glow given off by the artery wall, which reflects what the tissue is made of, while the other maps how light scatters back from that tissue to reveal its fine structure. Together, the pair produces colour images of the wall as the catheter rotates and pulls back, covering a stretch of about eighty millimetres in roughly two seconds. That speed matters in a beating heart, where a clinician has only a brief window to capture a clean picture of a moving target.

Today's standard heart catheter checks already show the shape and texture of a vessel wall, yet they leave out the chemistry that helps determine whether a deposit is stable or ready to break apart. A deposit can look modest while carrying inflammation or other warning signs, and a rupture can suddenly form a clot that blocks blood flow and triggers a heart attack. By adding chemical information to the structural picture, the new scan aims to separate deposits that mainly need watching from those that may need earlier or more aggressive treatment, according to the research team.

From Lab Bench to First Patients

The path to human testing ran through animal studies and experiments on donated human artery samples, steps that let engineers refine a catheter small and flexible enough for coronary vessels. Regulators then cleared the system for investigational use in a small first group, and imaging for the final volunteer wrapped up in August. The researchers now plan to expand testing to more patients, a necessary step before any claim about preventing heart attacks can be made with confidence.

The stakes are high because cardiovascular disease remains the leading cause of death in the United States, and plaque buildup can also lead to stroke and other serious conditions. Treatment for narrowed vessels often involves placing a stent, and decisions about where to put it, and which medicines to pair with it, shape how well that treatment holds up over time. A scan that shows both composition and structure could help clinicians choose those placements more precisely, rather than judging a vessel by its narrowest point alone. Readers interested in other early-detection work can also see how blood clues are flagging prostate risk years early in a different field of medicine.

"Testing this device marks a major step toward advancing heart health," said Laura Marcu, the centre's founding director, who added that the technology could help clinicians understand how artery disease progresses and personalise treatment. The centre's interventional cardiology lead, who ran the patient testing, noted that the scan should reliably reveal chemical signs tied to inflammation and possible rupture or erosion, while cautioning that further research must establish the best ways to treat each type of deposit the device reveals.

There are clear limits to celebrate carefully. A first-in-human study is designed mainly to show that a device can be used safely and returns usable images, not to prove that it improves outcomes or saves lives. The group tested was small, the follow-up so far is short, and the scan's readings will need to be matched against real patient outcomes before doctors can act on them routinely. The team also acknowledges that cost, training and availability in ordinary catheter labs will matter as much as image quality in deciding whether the idea spreads.

For now, the result is a promising proof of concept with a concrete next step: bigger studies that test whether chemical-plus-structural imaging changes treatment decisions and, ultimately, patient health. If that evidence arrives, the humble Dual Imaging Heart Catheter could evolve from a camera for narrowing into an early-warning instrument for rupture risk. Related early-detection research includes a new kidney care tool that spots hidden disease earlier, another example of screening moving upstream, before symptoms force the issue.